MCID: SPR001
MIFTS: 22

Superficial Urinary Bladder Cancer

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Superficial Urinary Bladder Cancer

MalaCards integrated aliases for Superficial Urinary Bladder Cancer:

Name: Superficial Urinary Bladder Cancer 12 15
Carcinoma of Urinary Bladder, Superficial 70
Superficial Urinary Bladder Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7371
NCIt 50 C27474
SNOMED-CT 67 425231005
UMLS 70 C1336527

Summaries for Superficial Urinary Bladder Cancer

Disease Ontology : 12 A carcinoma of bladder that originates in the epithelial cells (the internal lining) of the bladder wall and is limited to this area.

MalaCards based summary : Superficial Urinary Bladder Cancer, also known as carcinoma of urinary bladder, superficial, is related to bladder cancer and transitional cell carcinoma. An important gene associated with Superficial Urinary Bladder Cancer is TCHH (Trichohyalin). The drugs Epirubicin and Doxorubicin have been mentioned in the context of this disorder. Related phenotype is vision/eye.

Related Diseases for Superficial Urinary Bladder Cancer

Diseases related to Superficial Urinary Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 bladder cancer 10.6
2 transitional cell carcinoma 10.2
3 in situ carcinoma 10.2
4 urethral stricture 10.0
5 47,xyy 10.0
6 urinary tract infection 10.0
7 acute cystitis 10.0
8 cystitis 10.0
9 bladder urothelial carcinoma 10.0
10 choriocarcinoma of ovary 9.7 SARNP PFAS

Graphical network of the top 20 diseases related to Superficial Urinary Bladder Cancer:



Diseases related to Superficial Urinary Bladder Cancer

Symptoms & Phenotypes for Superficial Urinary Bladder Cancer

MGI Mouse Phenotypes related to Superficial Urinary Bladder Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.02 CTPS1 CYP1B1 MSH3 PFAS SARNP

Drugs & Therapeutics for Superficial Urinary Bladder Cancer

Drugs for Superficial Urinary Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
3 Antibiotics, Antitubercular Phase 4
4
Liposomal doxorubicin Phase 4 31703
5 Anti-Bacterial Agents Phase 4
6
BCG vaccine Approved, Investigational Phase 2, Phase 3
7 Adjuvants, Immunologic Phase 2, Phase 3
8 Immunologic Factors Phase 2, Phase 3
9 Antiviral Agents Phase 2, Phase 3
10 interferons Phase 2, Phase 3
11 Interferon-alpha Phase 2, Phase 3
12 Anti-Infective Agents Phase 2, Phase 3
13 Vaccines Phase 2, Phase 3
14 Mitomycins

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial Completed NCT02214602 Phase 4 Epirubicin
2 A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer Completed NCT00330707 Phase 2, Phase 3 Bacillus Calmette Guerin and interferon alpha
3 Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Completed NCT01803295

Search NIH Clinical Center for Superficial Urinary Bladder Cancer

Genetic Tests for Superficial Urinary Bladder Cancer

Anatomical Context for Superficial Urinary Bladder Cancer

Publications for Superficial Urinary Bladder Cancer

Articles related to Superficial Urinary Bladder Cancer:

(show all 33)
# Title Authors PMID Year
1
BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling. 61
30358081 2019
2
A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer. 61
28677313 2017
3
Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment. 61
26813865 2016
4
Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. 61
22757606 2012
5
Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer. 61
22819699 2012
6
[Hemocyanins as immunostimulants]. 61
21773663 2011
7
Evaluation of the Value of Combined Urine Cytology and Cystoscopy for Follow-up of Superficial Transitional Cell Carcinoma of the Urinary Bladder. 61
21860467 2010
8
[Disseminated BCG infection in patients with urinary bladder carcinoma]. 61
20491388 2009
9
[The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer]. 61
17310587 2007
10
Cell-nuclear data reduction and prognostic model selection in bladder tumor recurrence. 61
17008071 2006
11
[Local thermotherapy with rabdosia liquid as prophylactic measure for recurrence of superficial urinary bladder carcinoma: a non-randomized contemporary controlled study]. 61
16398435 2005
12
Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. 61
16334168 2005
13
Outcomes of hand-assisted laparoscopic nephroureterectomy for managing upper urinary tract transitional cell carcinoma--China Medical University Hospital experience. 61
15833509 2005
14
Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. 61
15647110 2005
15
[Use of BCG in superficial urinary bladder carcinoma]. 61
11594217 2001
16
Role of ultrasonography and urinary cytology in diagnosing recurrence of superficial urinary bladder cancer compared to cystoscopy. 61
11692897 2001
17
Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. 61
10604379 2000
18
Ion exchange tumor targeting: a new approach. 61
10541343 1999
19
Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. 61
10398139 1999
20
Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy. 61
10408303 1999
21
Effects of intravesical instillation of 5-fluorouracil and interferon in patients with recurrent superficial urinary bladder carcinoma. A clinical and pharmacodynamic study. 61
9290163 1997
22
Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. 61
8319187 1993
23
Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments. 61
8291866 1993
24
[Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study]. 61
2058066 1991
25
[Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy]. 61
1904118 1991
26
Instillation therapy in superficial urinary bladder cancer. Finnbladder Group. 61
1785001 1991
27
[Usefulness of ATP-sensitivity-assay of intravesical instillation therapy of anti-cancer agents for superficial bladder cancer]. 61
2374328 1990
28
[Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer]. 61
2655259 1989
29
The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. 61
2923091 1989
30
[Prognostic significance of dysplastic urothelial changes for the rate of recurrence in superficial urinary bladder cancer]. 61
3439374 1987
31
Methodologies for quantifying the results of intravesical chemotherapy of superficial tumors of the bladder. 61
3937002 1985
32
Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. 61
6508201 1984
33
[The effect of intravesical chemotherapy on superficial urinary bladder cancer]. 61
6203382 1983

Variations for Superficial Urinary Bladder Cancer

Expression for Superficial Urinary Bladder Cancer

Search GEO for disease gene expression data for Superficial Urinary Bladder Cancer.

Pathways for Superficial Urinary Bladder Cancer

GO Terms for Superficial Urinary Bladder Cancer

Biological processes related to Superficial Urinary Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamine metabolic process GO:0006541 8.62 PFAS CTPS1

Molecular functions related to Superficial Urinary Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ligase activity GO:0016874 8.62 PFAS CTPS1

Sources for Superficial Urinary Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....